Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Hope for avoiding chemo in patients with Hodgkins lymphoma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 1728
Rating:

Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy

Data presented at ASH 2014 indicates that brentuximab vedotin was "impressive" as single therapy for patients with Hodgkins lymphoma, bringing complete responses in 11 out of 12 patients investigated for their response to the drug as monotherapy before going onto receive ABVD.

Prof Massimo Federico told ecancertv that the initial success suggests that longer brentuximab courses could be used in place of chemotherapy or radiotherapy in some patients.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation